Gastroesophageal Junction Adenocarcinoma Clinical Trials in Clermont-Ferrand
3 recruitingClermont-Ferrand, France
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled284 locationsNCT06764875
Recruiting
Phase 2
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaEsophagus Adenocarcinoma
UNICANCER118 enrolled29 locationsNCT05476796
Recruiting
Not Applicable
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Pancreatic CancerAdenocarcinomaResectable Pancreatic Adenocarcinoma+3 more
University Hospital, Clermont-Ferrand100 enrolled1 locationNCT06649474